Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027
Covered in this story
Analyst targets on Foghorn Therapeutics Inc
- H.C. Wainwright: $2.02 → $5 by Oct 2027 · Buy via Investing.com
- Stifel: $2.92 → $5 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $FHTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Foghorn Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.